Dimethyltryptamine/harmine

Dimethyltryptamine/harmine is a combination of dimethyltryptamine, a tryptamine serotonin receptor agonist and serotonergic psychedelic, and harmine, a β-carboline reversible inhibitor of monoamine oxidase A, which is under development for the treatment of mood disorders.
It is a form of pharmahuasca, in which DMT is combined with a synthetically produced monoamine oxidase inhibitor as opposed to a plant-derived form such as Banisteriopsis caapi as in ayahuasca. Harmine, acting as a RIMA, inhibits the metabolism of DMT, in turn greatly potentiating DMT and allowing it to become orally active.
The combination is being developed by Reconnect Labs. As of August 2023, it is in phase 1 clinical trials.